AusPAR: Lixisenatide - Therapeutic Goods Administration
... patients with T2DM, mean apparent half-life generally ranged from 1.5 to 4.5 h and the mean apparent clearance ranged from 20 to 67 L/h at steady state. The same test method, a ligand binding assay designated DOH0498, was used for the determination of lixisenatide in Studies BDR6864 and BEQ11094. Ho ...
... patients with T2DM, mean apparent half-life generally ranged from 1.5 to 4.5 h and the mean apparent clearance ranged from 20 to 67 L/h at steady state. The same test method, a ligand binding assay designated DOH0498, was used for the determination of lixisenatide in Studies BDR6864 and BEQ11094. Ho ...
Design and Characterization of Fast Dissolving Films of Valsartan
... angiotensin receptor (7, 8). Hence, it requires rapid absorption and high bioavailability in patient point of view. VAL is absorbed over 4 hours, and its bioavailability is only about 20 to 25%. Fed conditions delay the absorption of VAL (9). In chronic hypertensive patients, blood pressure often sh ...
... angiotensin receptor (7, 8). Hence, it requires rapid absorption and high bioavailability in patient point of view. VAL is absorbed over 4 hours, and its bioavailability is only about 20 to 25%. Fed conditions delay the absorption of VAL (9). In chronic hypertensive patients, blood pressure often sh ...
Formulation And Evaluation Of Clotrimazole Solid Dispersion
... effect of the drug to the surface of the skin or within the skin. Skin is one of the most readily accessible organs on human body for topical administration and is the main route of topical drug delivery system. It affords to maintain applied preparation intact for a prolonged time and this has resu ...
... effect of the drug to the surface of the skin or within the skin. Skin is one of the most readily accessible organs on human body for topical administration and is the main route of topical drug delivery system. It affords to maintain applied preparation intact for a prolonged time and this has resu ...
DEVELOPMENT AND CHARACTERIZATION OF FLUTAMIDE CONTAINING SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEM (SMEDDS)
... (2-methyl-N-[4-nitro-3(trifloromethyl) phenyl] propanamide is a nonsteroidal pure antiandrogen that acts by inhibiting the uptake and/or binding of ...
... (2-methyl-N-[4-nitro-3(trifloromethyl) phenyl] propanamide is a nonsteroidal pure antiandrogen that acts by inhibiting the uptake and/or binding of ...
Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis
... their sub-micron size and to their hydrophilicity PNPs can penetrate deep into tissue through capillaries and reach the target tissue where they can be taken up by the cells (Vinagradov et al. 2002). Moreover, nanoparticles can be functionalized above the surface using residual reactive ending-group ...
... their sub-micron size and to their hydrophilicity PNPs can penetrate deep into tissue through capillaries and reach the target tissue where they can be taken up by the cells (Vinagradov et al. 2002). Moreover, nanoparticles can be functionalized above the surface using residual reactive ending-group ...
Allergy - Australian Medicines Handbook
... The risk or severity of anaphylactic reactions may be affected by other factors, such as exercise, infections, other diseases (eg asthma), drugs (eg NSAIDs), alcohol. There are no clinically relevant differences between anaphylactic reactions that are allergic (mediated by IgE or other immune comple ...
... The risk or severity of anaphylactic reactions may be affected by other factors, such as exercise, infections, other diseases (eg asthma), drugs (eg NSAIDs), alcohol. There are no clinically relevant differences between anaphylactic reactions that are allergic (mediated by IgE or other immune comple ...
BUPROPION HYDROCHLORIDE
... initial dose is tolerated, an increase to 150 mg twice daily is recommended as early as day 4. There should be an interval of at least 8 hours between doses. An increase in dosage to the maximum of 400 mg/day given as 200 mg twice daily may be considered for patients in whom no clinical improvement ...
... initial dose is tolerated, an increase to 150 mg twice daily is recommended as early as day 4. There should be an interval of at least 8 hours between doses. An increase in dosage to the maximum of 400 mg/day given as 200 mg twice daily may be considered for patients in whom no clinical improvement ...
DOBUTamine
... Treatment: To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdosage, consider the possibility of ...
... Treatment: To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdosage, consider the possibility of ...
1 FLAGYL® metronidazole tablets To reduce the development of
... in rats at doses up to five times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to metronidazole. No fetotoxicity was observed when metronidazole was administered orally to pregnant mice at 20 mg/kg/day, approximately one and a half times the most freque ...
... in rats at doses up to five times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to metronidazole. No fetotoxicity was observed when metronidazole was administered orally to pregnant mice at 20 mg/kg/day, approximately one and a half times the most freque ...
LOCAL DRUG DELIVERY IN PERIODONTICS: A STRATEGIC INTERVENTION Review Article
... resistance have been described.10 Some studies also reported poor results due to the fact that the active product could not achieve an adequate concentration at the site of action and/or due to the inability of the active product to be retained locally for a sufficient period of time. These drawback ...
... resistance have been described.10 Some studies also reported poor results due to the fact that the active product could not achieve an adequate concentration at the site of action and/or due to the inability of the active product to be retained locally for a sufficient period of time. These drawback ...
View eBook - Absorption Systems
... knockdown of one efflux transporter at a time: BCRP, P-gp, MRP2. We use them in the vectorial transport format in two different ways: 1. Efflux ratio in control vs. knockdown cells identifies which efflux transporter(s) handle a test compound. 2. Using the probe substrate, cladribine, in P-gp knoc ...
... knockdown of one efflux transporter at a time: BCRP, P-gp, MRP2. We use them in the vectorial transport format in two different ways: 1. Efflux ratio in control vs. knockdown cells identifies which efflux transporter(s) handle a test compound. 2. Using the probe substrate, cladribine, in P-gp knoc ...
PREPARATION AND CHARACTERIZATION OF ORODISPERSIBLE TABLETS OF CANDESARTAN
... as diluents. Formulated orodispersible tablets were evaluated for weight variation, friability, disintegration time, drug content, wetting time, water absorption ratio and in vitro drug release. Results: The results show that the presence of a superdisintegrant and MCC is desirable for orodispersion ...
... as diluents. Formulated orodispersible tablets were evaluated for weight variation, friability, disintegration time, drug content, wetting time, water absorption ratio and in vitro drug release. Results: The results show that the presence of a superdisintegrant and MCC is desirable for orodispersion ...
Mock IRAS form - Health Research Authority
... Study limited to working with human tissue samples (or other human biological samples) and data (specific project only) Study limited to working with data (specific project only) Research tissue bank Research database ...
... Study limited to working with human tissue samples (or other human biological samples) and data (specific project only) Study limited to working with data (specific project only) Research tissue bank Research database ...
The Role of Subcutaneous Ketorolac for Pain Management
... P = .04). High doses (>105 mg/day) of ketorolac were also associated with increased risk, which was further increased in people older than 65 years of age.3 Renal toxicity has been mainly demonstrated through case report data, even in patients who only received a single dose.1 In light of these find ...
... P = .04). High doses (>105 mg/day) of ketorolac were also associated with increased risk, which was further increased in people older than 65 years of age.3 Renal toxicity has been mainly demonstrated through case report data, even in patients who only received a single dose.1 In light of these find ...
& Memorandum .DHN81W
... highesttolerable dose was used here as the high dose). After the second dosing, one group of mice was sacrificed24 hours later and the second group of mice was sacrificed48 hours later. According to the regular method for makingslides,the time when the highest number of micronucleatedcellswere detec ...
... highesttolerable dose was used here as the high dose). After the second dosing, one group of mice was sacrificed24 hours later and the second group of mice was sacrificed48 hours later. According to the regular method for makingslides,the time when the highest number of micronucleatedcellswere detec ...
022571Orig1s000 MEDICAL REVIEW(S) CENTER FOR DRUG EVALUATION AND RESEARCH
... the rate of salivation by preventing the stimulation of these receptors. Current submission is being reviewed for the use of this drug in the treatment of excessive drooling secondary to different neurologic impairments including cerebral palsy. This would involve chronic exposure of the subjects to ...
... the rate of salivation by preventing the stimulation of these receptors. Current submission is being reviewed for the use of this drug in the treatment of excessive drooling secondary to different neurologic impairments including cerebral palsy. This would involve chronic exposure of the subjects to ...
PRIAPISM INDUCED WITH SINGLE ORAL DOSE OF SILDENAFIL: A RARE CASE REPORT Research Article
... arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely.10 An extensive review of the published medical literature and the manufacturer's clinical trial and post marketing database id ...
... arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely.10 An extensive review of the published medical literature and the manufacturer's clinical trial and post marketing database id ...
Nembutal Sales Aid - Akorn Pharmaceuticals
... and dispensing of sedative-hypnotic barbiturates should be limited to the amount required for the interval until the next appointment. Abrupt cessation after prolonged use in the dependent person may result in withdrawal symptoms, including delirium, convulsions, and possibly death. Barbiturates sho ...
... and dispensing of sedative-hypnotic barbiturates should be limited to the amount required for the interval until the next appointment. Abrupt cessation after prolonged use in the dependent person may result in withdrawal symptoms, including delirium, convulsions, and possibly death. Barbiturates sho ...
Prevention and Treatment of VTE
... High prevalence of VTE – Almost all hospitalized patients have one or more risk factors for VTE – The incidence of DVT is as high as 80% in some hospitalized patient groups – Hospital-acquired DVT and PE are usually clinically silent – It is difficult to predict which at-risk patients will develop ...
... High prevalence of VTE – Almost all hospitalized patients have one or more risk factors for VTE – The incidence of DVT is as high as 80% in some hospitalized patient groups – Hospital-acquired DVT and PE are usually clinically silent – It is difficult to predict which at-risk patients will develop ...
Ibogaine in opioid detoxification
... mentioned methadone as a cause of death or overdose during methadone treatment); 102,615 TEs (1 methadone-related death /364 TEs)2,3 •Methadone (Utah 2004; Controlled substance and medical examiner databases): 110 fatalities in which medical examiner mentioned methadone as a cause of death; 52,350 m ...
... mentioned methadone as a cause of death or overdose during methadone treatment); 102,615 TEs (1 methadone-related death /364 TEs)2,3 •Methadone (Utah 2004; Controlled substance and medical examiner databases): 110 fatalities in which medical examiner mentioned methadone as a cause of death; 52,350 m ...
antimicrobial use
... In March 2002, an antimicrobial order form was initiated at UWHC, to improve the use of antimicrobial therapy at UWHC. This form has for the first time provided the capacity of obtaining real-time information on antimicrobial usage patterns, and has formed the basis for intensified efforts to improv ...
... In March 2002, an antimicrobial order form was initiated at UWHC, to improve the use of antimicrobial therapy at UWHC. This form has for the first time provided the capacity of obtaining real-time information on antimicrobial usage patterns, and has formed the basis for intensified efforts to improv ...
GUIDELINE FOR GOOD CLINICAL PRACTICE
... other relevant information (e.g., pertinent animal data or product quality issues that may have clinical implications). The Clinical Overview is primarily intended for use by regulatory agencies in the review of the clinical section of a marketing application. It should also be a useful reference to ...
... other relevant information (e.g., pertinent animal data or product quality issues that may have clinical implications). The Clinical Overview is primarily intended for use by regulatory agencies in the review of the clinical section of a marketing application. It should also be a useful reference to ...
Bupivacaine Hydrochloride Injection, USP Rx
... for dental use, in many patients up to 7 hours. The duration of anesthetic effect is prolonged by the addition of epinephrine 1:200,000. Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug the higher the percentage of drug bound ...
... for dental use, in many patients up to 7 hours. The duration of anesthetic effect is prolonged by the addition of epinephrine 1:200,000. Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug the higher the percentage of drug bound ...
ANSI HIBC 3.1 Positive Identification for Patient Safety: Part 1
... Positive Identification for Patient Safety; Part 1: Medication Delivery resulted from work carried out by Massachusetts General Hospital (MGH), a hospital within the Partners Healthcare System. MGH embarked on a project in 2004 to develop a safer system for the administration of medication to patien ...
... Positive Identification for Patient Safety; Part 1: Medication Delivery resulted from work carried out by Massachusetts General Hospital (MGH), a hospital within the Partners Healthcare System. MGH embarked on a project in 2004 to develop a safer system for the administration of medication to patien ...
Page 1 of 9 Clinical Policy: aflibercept (Eylea), ranibizumab
... (Diagnoses/Indications for which coverage is NOT authorized) II. Continued Therapy A. All Indications (must meet all): 1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria; 2. Documentation of positive r ...
... (Diagnoses/Indications for which coverage is NOT authorized) II. Continued Therapy A. All Indications (must meet all): 1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria; 2. Documentation of positive r ...